Turning Point Therapeutics Inc.
https://tptherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Turning Point Therapeutics Inc.
China Deal Watch: Four Biotechs Kick Off May With Multiple In/Out Deals
Four Chinese biotech companies reach in- and out-licensing deals covering antibody drug conjugates, small molecules and vaccines as they continue to pursue and develop innovation.
Turning Point ROS1/TRK Inhibitor Repotrectinib Could Stand Out On Durability
The drug showed a high durability of response in ROS1-positive NSCLC patients, a factor that could give it significant differentiation compared with approved agents.
Deal Watch: J&J Partners On Bispecific Antibody R&D With F-Star, Xencor
Janssen Biotech adds to its bispecific antibody pipeline for cancer via pair of collaborations. Ipsen and Accent pair up to investigate new target for acute myeloid leukemia.
Keeping Track: J&J Amivantamab, Infectious Disease Agents From Iterum, VBI And Atox Submitted; Another Furoscix CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- TP Therapeutics, Inc